Synapse - Andrew Zelenetz

Results (785)

Prevalence of Hepatitis B surface antigen and Hepatitis B core antibody in a cancer patient population initiating immunosuppression: One year data from a novel pilot program

Meeting Abstract

Mendelsohn, R.; Taur, Y.; Kamboj, M.; Sepkowitz, K.; Zelenetz, A. D.; Nagula, S.; Ludwig, E.
Hepatology (2010)

Fulltext@MSK | Save

Genome-wide association analysis of familial lymphoma

Meeting Abstract

Kirchhoff, T.; Joseph, V.; Brown, J.; Dutra Clarke, A.; Gaudet, M. M.; Paltiel, O.; Ben-Yehuda, D.; McGhee, K.; Gold, B.; Devlin, V.; more...
Cancer Research (2010)

Fulltext@MSK | Save

Low proliferation index may be associated with longer time to first therapy in low grade follicular lymphoma

Meeting Abstract

Kedmi, M.; Hedvat, C. V.; Maragulia, J.; Zelenetz, A. D.
Blood (2010)

Fulltext@MSK | Save

Final results of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Hamlin, P. A. Jr; Rodriguez, M. A.; Noy, A.; Portlock, C. S.; Straus, D.; McLaughlin, P.; Pro, B.; Fayad, L.; Hagemeister, F.; Wegner, B.; more...
Blood (2010)

Fulltext@MSK | Save

Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience

Journal Article

Edwards-Bennett, S. M.; Jacks, L. M.; Moskowitz, C. H.; Wu, E. J.; Zhang, Z.; Noy, A.; Portlock, C. S.; Straus, D. J.; Zelenetz, A. D.; Yahalom, J.
Annals of Oncology (2010)

Fulltext@MSK | Save

A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Journal Article

Younes, A.; Vose, J. M.; Zelenetz, A. D.; Smith, M. R.; Burris, H. A.; Ansell, S. M.; Klein, J.; Halpern, W.; Miceli, R.; Kumm, E.; more...
British Journal of Cancer (2010)

Fulltext@MSK | Save

Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma

Journal Article

Schaffel, R.; Hedvat, C.; Teruya-Feldstein, J.; Persky, D.; Maragulia, J.; Lin, D.; Portlock, C. S.; Moskowitz, C. H.; Zelenetz, A. D.
Annals of Oncology (2010)

Fulltext@MSK | Save

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

Journal Article

O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Gerecitano, J.; Gonen, M.; Dumitrescu, O.; Sarasohn, D.; Butos, J.; more...
Clinical Cancer Research (2010)

Fulltext@MSK | Save

Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? - Reply